Acute viral hepatitis - Symptoms, Causes, Treatment & Prevention

```html

Overview

Acute viral hepatitis is a sudden inflammation of the liver caused by infection with one of several hepatitis viruses (most commonly hepatitis A, B, C, D, or E). The condition usually develops within weeks after exposure and can range from a mild, self‑limited illness to severe liver dysfunction.

• Who it affects: All ages can be infected, but incidence varies by virus and geography. Hepatitis A and E are most common in children and travelers to low‑income regions, whereas hepatitis B and C affect adults through sexual contact, injection drug use, or perinatal transmission.
• Prevalence: According to the World Health Organization (WHO), in 2022 there were an estimated:
  • ≈ 1.4 million new cases of hepatitis A annually.
  • ≈ 296 million people living with chronic hepatitis B and C; a fraction of these experience acute flare‑ups each year.
  • ≈ 20 million new hepatitis E infections, primarily in Asia and Africa.

Symptoms

Symptoms usually appear 2–6 weeks after exposure and may last from a few days to several weeks. Not everyone experiences every symptom.

Symptom	Description
Fatigue	Persistent tiredness that interferes with daily activities.
Jaundice	Yellowing of the skin and eyes due to elevated bilirubin.
Dark urine	Urine becomes tea‑colored because of bilirubin excretion.
Pale stools	Stools lose their normal brown color.
Abdominal pain	Often a dull ache in the upper right quadrant where the liver sits.
Nausea & vomiting	May accompany loss of appetite.
Fever & chills	Low‑grade fever is common, especially with hepatitis A and E.
Loss of appetite	Feeling “full” quickly, leading to weight loss.
Muscle aches	Generalized body aches, similar to flu‑like illness.
Itching (pruritus)	Occasional skin itching due to bile salt deposition.

Causes and Risk Factors

The “viral” part of the name indicates the underlying cause: infection with a hepatitis virus. Each virus has distinct transmission routes.

Hepatitis A (HAV)

• Fecal‑oral transmission – contaminated food or water.
• Close contact with an infected person (e.g., household, daycare).
• Risk factors: travel to endemic areas, inadequate sanitation, men who have sex with men (MSM).

Hepatitis B (HBV)

• Blood‑borne and sexual transmission.
• Perinatal transmission from mother to infant.
• Risk factors: unprotected sex, injection drug use, health‑care workers, tattoos/piercings with non‑sterile equipment.

Hepatitis C (HCV)

• Primarily blood‑borne.
• Risk factors: sharing needles, inadequate sterilization of medical equipment, transfusion of unscreened blood (rare in high‑income countries).

Hepatitis D (HDV)

• Requires co‑infection with HBV.
• Risk factors mirror HBV.

Hepatitis E (HEV)

• Fecal‑oral, similar to HAV, but often linked to undercooked pork or wild game.
• Higher severity in pregnant women.

General Risk Enhancers

• Living in or traveling to regions with poor sanitation.
• Having a chronic liver disease (e.g., cirrhosis) – infections can become more severe.
• Immunosuppression (HIV, organ transplant, chemotherapy).

Diagnosis

Diagnosis combines clinical suspicion with laboratory and imaging studies.

Laboratory Tests

• Liver function panel: Elevated alanine aminotransferase (ALT) and aspartate aminotransferase (AST) often >10× the upper limit of normal. Bilirubin, alkaline phosphatase, and INR may also rise.
• Serologic assays:
  • Anti‑HAV IgM – indicates acute hepatitis A.
  • HBsAg + anti‑HBc IgM – acute hepatitis B.
  • Anti‑HCV IgM or HCV RNA PCR – acute hepatitis C.
  • Anti‑HEV IgM – acute hepatitis E.
• Viral load PCR: Quantifies viral RNA/DNA for HBV, HCV, HDV; useful for prognosis.

Imaging

• Abdominal ultrasound: Rules out biliary obstruction and evaluates liver size, texture, and signs of acute inflammation.
• CT or MRI rarely needed unless complications (e.g., hepatic necrosis) are suspected.

Other Assessments

• Complete blood count – may show mild leukopenia or thrombocytopenia.
• Coagulation profile – prolonged INR suggests impaired synthetic function.

Treatment Options

Most acute viral hepatitis cases are self‑limited and require supportive care. Antiviral therapy is virus‑specific and indicated only for certain infections.

Supportive Care (All Types)

• Rest and adequate hydration.
• Balanced diet – emphasize protein, complex carbs, and healthy fats; avoid alcohol and hepatotoxic drugs (e.g., acetaminophen >2 g/day).
• Management of nausea: anti‑emetics such as ondansetron.
• Control of itching: cholestyramine or antihistamines.

Virus‑Specific Therapies

• Hepatitis A & E: No specific antiviral; recovery is usually complete within 2–3 months.
• Hepatitis B:
  • Antiviral agents (e.g., tenofovir, entecavir) are reserved for severe acute hepatitis, fulminant liver failure, or patients at high risk of chronicity (immunocompromised, >40 y, high viral load).
• Hepatitis C:
  • Direct‑acting antivirals (DAAs) are standard for chronic infection; acute infection may be observed, but treatment is considered if rapid progression is evident.
• Hepatitis D:
  • Pegylated interferon‑α is the only approved therapy, but response rates are modest.

Procedures for Severe Cases

• Hospitalization: Indicated for encephalopathy, coagulopathy (INR > 1.5), or rapid bilirubin rise.
• Liver transplant: Considered in fulminant hepatic failure when MELD score > 30 or when there is no improvement after 48‑72 hours of intensive care.

Living with Acute Viral Hepatitis

While the disease is usually short‑term, following a structured plan can ease symptoms and protect the liver.

Daily Management Tips

1. Hydration: Aim for 2–3 liters of water daily unless fluid restriction is ordered.
2. Nutrition: Small, frequent meals; incorporate fruits, vegetables, and lean protein. Limit saturated fats and fried foods.
3. Avoid Alcohol & Drugs: Alcohol can worsen liver injury; avoid recreational drugs and limit over‑the‑counter medications that affect the liver.
4. Sleep: 7–9 hours/night to aid immune recovery.
5. Medication Review: Discuss all prescriptions and supplements with your provider; some herbs (e.g., kava, comfrey) are hepatotoxic.
6. Follow‑up Labs: Repeat liver function tests every 1–2 weeks until normalization.
7. Vaccination: If you had hepatitis A, you are protected; otherwise, get HAV and HBV vaccines after recovery.

Emotional Support

• Join support groups (e.g., Hepatitis Foundation). Depression is common; seek counseling if mood changes persist.

Prevention

• Vaccination: Safe, effective vaccines exist for hepatitis A and B. The WHO recommends universal infant HBV vaccination and HAV vaccination for travelers and high‑risk groups.
• Safe Food & Water: Drink bottled or boiled water, peel fruits, avoid raw shellfish in endemic regions.
• Safe Sex: Use condoms, limit number of partners, and get screened regularly.
• Injection Safety: Never share needles; use sterile equipment for tattoos or piercings.
• Hand Hygiene: Wash hands with soap after using the bathroom and before handling food.
• Maternal Screening: Pregnant women should be screened for HBV and HEV; antiviral prophylaxis may be indicated for high HBV viral loads.

Complications

Most acute infections resolve without lasting damage, but complications can arise, especially in high‑risk individuals.

• Fulminant hepatic failure: Rapid loss of liver function, encephalopathy, coagulopathy; mortality > 70 % without transplant.
• Chronic infection: HBV, HCV, and HDV can become chronic, leading to cirrhosis, hepatocellular carcinoma (HCC), and liver failure.
• Co‑infection interaction: For example, HAV superinfection in chronic HBV/HCV patients markedly increases mortality.
• Renal dysfunction: Acute kidney injury occurs in up to 15 % of fulminant cases.
• Pancreatitis: Reported in severe hepatitis A and E.

When to Seek Emergency Care

References

• World Health Organization. Hepatitis Fact Sheets. 2023.
• Mayo Clinic. Acute Hepatitis. Updated 2024.
• CDC. Hepatitis A, B, C, D, and E – Prevention & Treatment. 2024.
• National Institutes of Health. Hepatitis B and C Treatment Guidelines. 2023.
• Cleveland Clinic. Acute Liver Failure. 2024.
• European Association for the Study of the Liver (EASL). Clinical Practice Guidelines for Hepatitis. 2022.

```